Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has
been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes
mainly through incretin hormone-mediated improvements in islet function [13]. Although
clinical studies to date indicate that fasting lipid levels are minimally affected by DPP-IV
inhibitor treatment [14-16], animal studies suggested that DPP-IV inhibition reduce
intestinal triglycerides (TG) absorption and apolipoprotein (apo) production [17] and
increased chylomicron catabolism [18]. Interestingly, a recent study supporting this
hypothesis showed that vildagliptin therapy was able to reduce postprandial intestinal
triglyceride-rich lipoproteins (TRL) particles in patients with type 2 diabetes [19].
Recently, our group has reported that sitagliptin treatment significantly reduced plasma apo
B-48 and TG concentrations in the postprandial state. Moreover, animal studies showed that
sitagliptin decreased intestinal secretion of intestinal apo B-48, mainly by increasing level
of glucagon-like peptide (GLP)-1 [20]. Therefore, the present study was designed to examine
the effects of sitagliptin on the kinetics of TRL apo B-48 and in patients with type 2
diabetes. A possible reduction in postprandial atherogenic TRL apo B-48-containing
lipoprotein levels by sitagliptin would add to therapeutic utility of this DPP-4 inhibitor
and suggest the potential to reduce cardiovascular risk in patients with type 2 diabetes.